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Abstract
Background: A large body of data derived from animal, epidemiological and clinical studies
indicate that n-3 polyunsaturated fatty acids have a favourable effect on the prognosis of patients
with cardiovascular disease in general, and on reducing sudden death in particular.
Depressed heart rate variability (HRV), an indicator of impairment of the autonomic nervous
system, has been shown to be a powerful predictor of subsequent mortality in patients surviving
an acute myocardial infarction. A multitude of studies have demonstrated this strong association,
suggesting that the imbalance in the sympathic/parasympathetic system may facilitate emergence of
ventricular arrhythmias.
Heart rate variability parameters will be assessed in the present study, with the primary objective
of evaluating the possible superiority of Omacor (a highly refined, concentrated omega-3 fatty acid)
versus placebo in improving HRV from baseline to endpoint in patients with recent uncomplicated
myocardial infarction. Both groups will receive optimal conventional treatment.
The study will also explore and quantify improvement in time domain HRV indices and will assess
the safety of administering Omacor to optimally treated post-infarction patients (conventional
treatment).
Methods: This multi-centre study will evaluate the effect of Omacor 1 g, o.d. on time-domain HRV
parameters in comparison to placebo o.d. in patients with recent uncomplicated transmural
myocardial infarction.
Patients will be screened during the first few days after the acute event as appropriate for the
patient's condition, and after obtaining informed consent. Based on inclusion/exclusion criteria, a
first 24-hour Holter recording will be performed. Two to five days later, screened patients still
eligible for the study will undergo a second 24-hour Holter recording. After the second Holter
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recording, all patients will be randomly allocated to treatment with Omacor 1 g, o.d. or placebo
o.d.
One hundred patients will be followed in double-blind fashion for a six-month period after 
randomization. Visits, including 24-hour Holter recording and assessment of adverse events, will 
take place at one-month intervals ± five days after randomization, i.e., six times in all.
Background
More than two decades ago, Bang and Dyerberg [1]
insightfully suggested that the low mortality from cardio-
vascular disease among Greenland Eskimos could be due
to the high concentration of n-3 polyunsaturated fatty
acids (PUFA) in their diet, which is high in marine verte-
brates. These observations triggered extensive studies that
focused on the role of marine oils in preventing coronary
heart disease [2–8] These studies began primarily in the
1980s, with ongoing efforts geared towards demonstrat-
ing that the biochemical and physiological effects of 3-n
fatty acids might be beneficial in preventing/reducing
atherosclerosis and depressive disorders through effects
on the basic functions of neurons and by preventing car-
diovascular arrhythmia through effects on the electro-
physiology of cardiac myocytes [9,10].
Results derived from laboratory animal studies [11–18],
epidemiological and metabolic studies [19–25] as well as
from clinical trials [26–32], provide evidence that PUFAs
exert some form of basic control over cardiac and neural
function, and that this has been largely overlooked,
despite current dietary guidelines, which recommend fish
consumption twice weekly for prevention of coronary
heart disease (CHD) [33].
Results of the GISSI-Prevenzione study [34] (11,323
patients with recent myocardial infarction randomized to
Omacor or vitamin E or the combination of the two)
showed significantly lower all-cause mortality in the
Omacor group, resulting largely from a 45% reduction in
sudden cardiac death during 3.5 years of follow-up.
Although the mechanism of action of Omacor is still
unknown, the benefits appear to relate to reducing lethal
arrhythmias rather than to changing cholesterol levels or
to any anticoagulant effect.
With the enormous burden of sudden cardiac death that
occurs virtually worldwide, and with cardiovascular dis-
ease poised to remain the number one killer in the world
for at least the next 30 years, there may be substantial pub-
lic health benefits to understanding PUFA's favourable
health effects.
The present study will explore the potential effects of
Omacor versus placebo on HRV through repeated assess-
ment of a number of time domain HRV parameters and
determination of plasma fatty acid concentrations in
patients who have experienced a recent uncomplicated
myocardial infarction.
Methods
Patient Population
HRV decreases in the early stages after an acute myocardial
infarction [35–42] and spontaneously and slowly nor-
malizes by the end of the first year [43,44]. Its assessment
as early as possible after the acute event [45], at pre-dis-
charge from the coronary care unit and on a monthly basis
during the ensuing six months therefore is expected to
predict further mortality [46].
In the context of the current study, it is expected that
improvement in the HRV parameters of actively treated
(as compared to placebo treated) patients will signifi-
cantly diminish risk for arrhythmia-related sudden death.
Subjects will be recruited from the coronary care units of
four tertiary hospitals in Poland and from four tertiary
hospitals in Lithuania. The study is sponsored by Solvay
Pharmaceuticals GmbH, Hannover, Germany and will be
carried out in collaboration with Quantum Research, UK
[47] and Scope International Life Sciences, Germany [48].
Potentially eligible patients with diagnosed acute myocar-
dial infarction will be selected by the cardiologist in
charge. Screening of these patients for the study will be
performed during the first 48–72 hours after the acute
event.
Subsequent to confirming eligibility and obtaining writ-
ten consent, a first 24-hour Holter recording will be
obtained and the following variables will be checked:
• Medical History
• Physical Examination
• BP and HR
• 12-lead ECG
• LVEF
• Troponin T/CK-MB (max values only)Current Controlled Trials in Cardiovascular Medicine 2003, 4 http://cvm.controlled-trials.com/content/4/1/2
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• 24-hour Holter recording (HRV)
• Laboratory (blood sampling + urine)
• Current medication
Two to five days later, when the patient's clinical condi-
tion is deemed stable and the patient remains eligible for
the study, a second 24-hour Holter recording is obtained.
The next day, patients are randomly allocated to treatment
with Omacor or placebo. The study flow diagram is noted
in Fig. 1.
Planned investigations during the monthly visits are dis-
played in the Investigation Schedule (Table 1).
Apart from study treatment, patients will receive individ-
ualized optimal treatment. Post-myocardial infarction fol-
low-up (secondary prevention) will be based on local
medical care, to include dietary and physical activity
advice.
Randomization and Blinding
The randomization list will be provided by the Depart-
ment of Clinical Supplies at Solvay Pharmaceuticals BV
with the program Almedica (Version 5.3). Patients will be
allocated in equal numbers to each sequence. A fixed
block size of patients will be used, and only complete
blocks of study medication will be provided to the centres.
Within each centre, randomization numbers will be used
in ascending order and patients will be allocated to rand-
omization code numbers in chronological order.
The randomization code for study medication will be pro-
vided to the investigator in separate sealed envelopes
labelled with study number and randomization code
numbers. The process of randomization will be
concealed.
Inclusion Criteria
Males and females aged 40 years or older, with recent sus-
tained acute myocardial infarction (AMI) will be eligible
for the study. Women of childbearing age will be subject
to pregnancy testing and will agree to maintain adequate
hormonal contraception.
Standard criteria for definition of acute, evolving or recent
AMI as well as for established AMI will be applied in the
patient screening process.
Signed informed consent is required before enrollment in
the study can proceed.
Exclusion Criteria
Specific exclusion criteria detailed in the study protocol
can be categorized into three groups:
1. Ineligibility based on the physician's decision (the car-
diologist in charge) that the patient has a clinical or
Study Design Figure 1
Study Design.
Omacor+ CT
Placebo + CT
S R V 1 V2 V3 V4 V5 V6
S – Screening, R – Randomization, V1-6 – Visits at 1 month interval ± five days,
CT – Conventional Treatment,       - 24 h Holter recordings
A
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hemodynamically unstable condition, or based on the
likelihood that the patient needs further invasive investi-
gation, a PTCA or a CABG.
2. The patient is in need of sustained antiarrhythmic ther-
apy (other than a beta-blocking agent administered in the
context of secondary prevention of MI).
3. The patient is suffering from a severe concomitant ill-
ness (related to any body organ or system) that is likely to
affect outcome assessment. Likewise, ineligibility will be
declared for patients anticipated to have compliance
problems, those participanting in another trial within the
past 30 days, those who are pregnant or lactating, or who
have a known hypersensitivity to the ingredients in Oma-
cor or intolerability to olive oil. In addition, patients with
diabetes mellitus type I and II will be excluded.
Study Outcomes
Prior and Concomitant Therapy
The study protocol calls for every patient to be treated
optimally by the physician in charge and to receive com-
prehensive, individualized advice regarding relevant die-
tary and physical activity prior to discharge from the
hospital. Visits are to be scheduled in the context of the
study (monthly visits during the ensuing six months).
Antiarrhythmic therapy is not permitted during study
involvement, except for the use of beta-blockers, since
these drugs are prescribed in most patients with recent
acute myocardial infarction (except for those with clear
contraindications). Patients on anticoagulant treatment
will undergo regular bleeding time checks according to
local routines.
Ethics and Informed Consent
With reference to paragraph 29 in the latest version of The
Declaration of Helsinki [49–52] (currently Declaration of
Edinburgh, 2000), use of placebo in this particular trial is
justified by the need to explore efficacy  of the product
under rigorous experimental conditions, as well as to
explore the mechanism of action responsible for the
favourable effect of the drug in the targeted population.
Written consent, involving provision of detailed informa-
tion regarding the study objectives, design, scope of the
intervention, risks and benefits, will be obtained for all
patients before intiating any study procedures.
Likewise, study documentation is to be subject to the scru-
tiny of local ethical committees in the two countries par-
ticipating in the study.
Sample Size and Statistical Analysis
For the primary efficacy variable, the change in (standard
deviation of all NN intervals (SDNN) from baseline to six
months (or last value in case of dropouts), a normal dis-
tribution with a standard deviation of σ = 50 ms is
assumed. If a two-sided two sample t-test with a level of
significance of α = 0.05 is applied, 45 patients per treat-
Table 1: InvestigationSchedule
S c r e e n R V 1V 2V 3V 4V 5V 6
Informed Consent *
Incl/Excl Criteria * *
Medical History *
Physical Exam * * *
B P  a n d  H R ********
ECG (12 lead) * * *
H R V ********
Lab * * *
C u r r e n t  m e d i c a t i o n ********
ASA
Diuretic
Beta-blocker
Ca antagonist
ACE-inhibitor
Ag II
Lipid lowering
Nitrates
A d v e r s e  E v e n t s *******
M e d .  d i s p e n s e *******
M e d .  c o l l e c t i o n *******Current Controlled Trials in Cardiovascular Medicine 2003, 4 http://cvm.controlled-trials.com/content/4/1/2
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ment group will be needed to achieve 80% statistical
power and to detect a mean difference of ∆ = 30 ms
between the treatment groups. One hundred patients will
be randomized.
For the primary efficacy parameter, the null hypothesis of
equal treatment group means will be tested against the
two-sided alternative of different treatment group means
at a level of significance of α = 0.05. For this, an analysis
of covariance (ANCOVA) model will be applied, to
include the treatment group and the medical center as fac-
tors and the baseline SDNN as a covariate.
In addition to the analysis of the total patient population,
the following subgroups of patients will be evaluated in
an exploratory fashion (the definition of these categories
may be changed during blind data review):
• Mildly decreased or normal HRV: SDNN > 100 ms
• Moderately decreased HRV: SDNN between 50 ms and
100 ms (inclusive)
• Severely decreased HRV: SDNN < 50 ms
Analysis of secondary efficacy parameters and analysis of
safety will be descriptive and exploratory.
Time Domain HRV Indices
The effect of treatment on time domain HRV parameters
will be assessed by comparing a number of parameters
derived from 24-hour Holter recordings. Time domain
indices that are to be assessed and analysed are displayed
in Table 2.
The SDNN and the HRV Triangular Index are estimates of
the overall HRV. SDNN estimates the long-term compo-
nents of the HRV, while the RMSSD estimates the short-
term components of the HRV. The sNN50 and 6% family
parameters provide useful information about the very
short term control of sinus rhythm dynamics in both
healthy and diseased individuals, related to parasympa-
thetic regulation.
The 24-hour Holter recordings will be analyzed using the
Lifecard CF system produced by Reynolds Medical, UK
[53]. A recording that cannot provide a minimum of 18
hours of data (including the whole night) out of the 24
hour Holter recording will be excluded from the analysis.
The Lifecard CF System [53]
The  Lifecard CF is a compact Holter Ambulatory ECG
Recorder utilizing a digital storage technique to store the
ECG recording onto a Compact Flash (CF) card.
The Lifecard CF is small and lightweight and provides con-
tinuous recording of 2 or 3 channels of ECG. It has a built
in display that enables one to monitor the ECG and pac-
ing detection during hook-up. This enables one to verify
the ECG quality before starting recording
Recordings are to be analyzed on the Reynolds Medical
Pathfinder Digital/700 Series Analysis System, fitted with
the appropriate Flashcard reader and will be performed by
highly trained analysts from Quantum Research, UK.
A study specific Instruction Manual for use of Holter
devices (including patient's hook-up) will be provided to
every investigative site.
Discussion
In patients who have experienced an MI, depressed heart
rate variability is considered to be a powerful predictor of
mortality and of arrhythmic complications (e.g., sympto-
matic sustained ventricular tachycardia). [8,54]. The pre-
dictive value of HRV is independent of other factors
Table 2: Time Domain HRV Parameters
Time-domain indices Description
Mean RR interval The average NN interval per hour; a single 24 hour average will be reported.
SDNN Standard deviation of the NN interval every hour; a single 24-hour average will be reported.
SDNNi Standard deviation of the NN interval in every 5 minutes; a single 24-hour average will be reported.
RMSSD The root mean square of successive differences of adjacent NN intervals; a single 24-hour average will be reported.
sNN50 Number of pairs of adjacent NN intervals differing by >50 ms; a single 24-hour value for the increases, decreases and 
total will be reported.
Triangular Index Total number of all NN intervals divided by the height of the histogram of all NN intervals measured on a discrete scale 
with bins of 1/128s; a single 24-hour average will be reported.
sNN6% Number of pairs of adjacent NN intervals differing by >6%; a single 24-hour value for the increases, decreases and total 
will be reported.
VPC > 10%/hour The number of hourly segments with > 10% SVE and VPCs will be reported and the absolute number of SVE and VPCs 
will also be reported.Current Controlled Trials in Cardiovascular Medicine 2003, 4 http://cvm.controlled-trials.com/content/4/1/2
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established for post-infarction risk stratification, such as
depressed left ventricular ejection fraction, increased ven-
tricular ectopic activity, and presence of late potential. For
prediction of all-cause mortality, the value of HRV is sim-
ilar to that of left ventricular ejection fraction, but HRV is
superior to left ventricular ejection fraction in predicting
arrhythmic events (sudden cardiac death and ventricular
tachycardia) [54]. This suggests that HRV is a stronger pre-
dictor of arrhythmic (as opposed to non-arrhythmic)
mortality.
The present study is not powered to detect differences in
clinical endpoints, in particular sudden death. However,
subgroup analysis will be performed in an attempt to
reveal eventual differences in HRV between sudden and
non-sudden cardiac death. It is not yet established
whether depressed HRV is part of the mechanism of
increased post-infarction mortality or is merely a marker
of poor prognosis. Available data suggest that depressed
HRV is not a simple reflection of sympathetic overdrive
and/or vagal withdrawal due to poor ventricular perform-
ance but that it also reflects depressed vagal activity, which
has a strong association with the pathogenesis of ventricu-
lar arrhythmias and sudden cardiac death [55]. A stratifi-
cation of patients on the basis of LVEF is not realistic,
given the small sample size; however, recording of LVEF in
all patients will allow for an exploratory analysis and
hypothesis generation.
Conclusions
Available evidence suggests that Omacor may provide
benefit in the immediate post-myocardial infarction
period. The present study will evaluate whether EPA and
DHA, which constitute 84% of the Omacor tablet,
improve time domain HRV parameters and surrogates for
arrhythmia-caused sudden death in post-myocardial inf-
arction patients.
Abbreviations
∆ difference
AE adverse event
ALAT alanine aminotranspherase
AMI acute myocardial infarction
ASAT aspartate aminotranspherase
AV atrioventricular
BP blood pressure
Ca2+ calcium ions
CCU coronary care unit
CK-MB creatine kinase – isoenzyme MB
CPT-I carnitine palmitoyltransferase I
CHD coronary heart disease
CRF case report form
DHA docosahexaenoic acid
ECG electrocardiogram
EPA eicosapentaenoic acid
FAT fatty acid transporter
GCP good clinical practice
GISSI Gruppo Italiano per lo Studio della Soprawivenza
nell'Infarto miocardico
HR heart rate
HRV heart rate variability
ICH International Conference on Harmonization
KI inhibition constant
K+ potassium ion
LBBB left bundle branch block
LVEDP left ventricular end diastolic pressure
LVESP left ventricular end systolic pressure
LVEF left ventricular ejection fraction
MI myocardial infarction
mRNA messenger RNA (carriers genetic information for
one single protein)
ms milliseconds
n, N number of patients
Na+ sodium ion
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Q wave negative deflection on the ECG occuring before
the QRS complex
QRS "complex" – depolarisation on ECG
p probability (5% alpha level)
p.o. per oral
PUFA polyunsaturated fatty acids
RBBB right bundle branch block
R wave positive deflection on ECG
RAAS rennin-angiotensin-aldosterone system
RMSSD the square root of the mean of the sum of the seg-
ments of differences
between adjacent NN intervals
RR average NN interval, per hour and 24 hour average
SAE serious adverse event
sNN50 number of adjacent NN intervals differing by >50
ms
sNN6% number of pairs of adjacent NN intervals differ-
ing by >6%
SDNN standard deviation of all NN intervals
SDANN standard deviation of the averages of NN inter-
vals in all 5 minutes
segments
SDNNi mean of the standard deviations of all NN inter-
vals for all 5 minutes
segments
ST "segment" – repolarisation phase on ECG
T troponine T
Triangular total number of all NN intervals devided by the
hight of the histogram of
all NN
Index intervals measured on a discrete scale with bins of
1/128s
VPB ventricular premature beats
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